$284.23 Million in Sales Expected for Prestige Consumer Healthcare Inc. (NYSE:PBH) This Quarter

Brokerages expect that Prestige Consumer Healthcare Inc. (NYSE:PBH – Get Rating) will report sales of $284.23 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Prestige Consumer Healthcare’s earnings, with the lowest sales estimate coming in at $279.80 million and the highest estimate coming in at $288.66 million. Prestige Consumer Healthcare posted sales of $269.18 million during the same quarter last year, which would indicate a positive year over year growth rate of 5.6%. The company is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Prestige Consumer Healthcare will report full-year sales of $1.12 billion for the current fiscal year, with estimates ranging from $1.12 billion to $1.13 billion. For the next year, analysts forecast that the firm will post sales of $1.15 billion, with estimates ranging from $1.13 billion to $1.16 billion. Zacks’ sales calculations are an average based on a survey of analysts that follow Prestige Consumer Healthcare.

Prestige Consumer Healthcare (NYSE:PBH – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.02. Prestige Consumer Healthcare had a net margin of 18.90% and a return on equity of 14.08%. The company had revenue of $266.94 million during the quarter, compared to the consensus estimate of $258.25 million. During the same quarter in the prior year, the firm earned $0.79 EPS. Prestige Consumer Healthcare’s quarterly revenue was up 12.3% on a year-over-year basis.

A number of research firms recently weighed in on PBH. StockNews.com began coverage on shares of Prestige Consumer Healthcare in a research report on Thursday, March 31st. They set a “buy” rating for the company. Oppenheimer raised shares of Prestige Consumer Healthcare from a “market perform” rating to an “outperform” rating and set a $63.00 price target for the company in a research report on Monday. Finally, Jefferies Financial Group raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating and raised their price target for the company from $65.00 to $70.00 in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $76.40.

Several institutional investors and hedge funds have recently made changes to their positions in PBH. PNC Financial Services Group Inc. raised its holdings in shares of Prestige Consumer Healthcare by 29.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,293 shares of the company’s stock valued at $184,000 after purchasing an additional 754 shares in the last quarter. Swiss National Bank raised its holdings in shares of Prestige Consumer Healthcare by 0.4% in the 3rd quarter. Swiss National Bank now owns 110,300 shares of the company’s stock valued at $6,189,000 after purchasing an additional 400 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Prestige Consumer Healthcare by 18.3% in the 3rd quarter. Jennison Associates LLC now owns 442,338 shares of the company’s stock valued at $24,820,000 after purchasing an additional 68,525 shares in the last quarter. Barclays PLC raised its holdings in shares of Prestige Consumer Healthcare by 107.6% in the 3rd quarter. Barclays PLC now owns 64,759 shares of the company’s stock valued at $3,633,000 after purchasing an additional 33,561 shares in the last quarter. Finally, CIBC Asset Management Inc raised its holdings in shares of Prestige Consumer Healthcare by 3.7% in the 3rd quarter. CIBC Asset Management Inc now owns 5,848 shares of the company’s stock valued at $328,000 after purchasing an additional 211 shares in the last quarter.

Prestige Consumer Healthcare stock opened at $57.57 on Wednesday. The company has a 50 day moving average price of $54.70. Prestige Consumer Healthcare has a 1-year low of $46.12 and a 1-year high of $63.83. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.25 and a current ratio of 2.04. The stock has a market cap of $2.89 billion, a PE ratio of 14.25, a price-to-earnings-growth ratio of 1.60 and a beta of 0.58.

Prestige Consumer Healthcare Company Profile (Get Rating)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

See Also